Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic Adenocarcinoma
Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic Adenocarcinoma
Recruiting · NCT04157127 · Registry updated 2026-08-26Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic Adenocarcinoma | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, endocrine system disorder, malignant endocrine neoplasm, malignant pancreatic neoplasm, neoplasm, pancreas disorder, pancreatic adenocarcinoma, pancreatic adenosquamous carcinoma, pancreatic neoplasm | Recruiting | Phase 1 | 2026-08-26 | NCT04157127 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Baylor College of Medicine | 267 |
| Diakonos Oncology Corporation | 3 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Baylor College of Medicine Medical Center - McNair Campus | Houston | United States | 1 |
| Baylor St. Lukes Medical Center | Houston | United States | 1 |
| Dan L. Duncan Cancer Center at Baylor College of Medicine | Houston | United States | 1 |